Investigation of the risk factors of vomiting during linezolid therapy : a retrospective observational study
| Autor: | Takezo Tsutsumi, Yoh Takekuma, Shungo Imai, Yuki Sato, Mitsuru Sugawara, Hitoshi Kashiwagi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Adult
Male medicine.medical_specialty Nausea Vomiting Comorbidity Logistic regression Drug Administration Schedule Adverse drug effects Young Adult Serotonin Agents Sex Factors Risk Factors Internal medicine Nausea and vomiting Medicine Electronic Health Records Humans Pharmacology (medical) Aged Retrospective Studies Pharmacology Aged 80 and over business.industry Medical record Body Weight Hyponatraemia Age Factors Linezolid Retrospective cohort study General Medicine Odds ratio Middle Aged Confidence interval Anti-Bacterial Agents Concomitant Female medicine.symptom business Hyponatremia |
| Zdroj: | European Journal of Clinical Pharmacology. 78(2):279-286 |
| ISSN: | 0031-6970 |
| Popis: | Purpose Some clinical studies have reported the occurrence of nausea and vomiting with linezolid (LZD) administration. However, no studies have evaluated nausea and vomiting as primary endpoints. In a previous study, we noted a possible relationship between LZD and vomiting, but risk factors were not identified. Therefore, the aim of the present study was to identify them. Methods Patients who received LZD 600 mg twice daily at Hokkaido University Hospital from September 2008 to April 2019 were enrolled in this retrospective observational study. Patient characteristics, concomitant medications, laboratory data, and the occurrence of vomiting were obtained from electronic medical records. Logistic regression analysis was performed to identify risk factors for vomiting, including age, sex, body weight, concomitant medications, and surgeries. Results A total of 496 patients were included in this study, of which 90 experienced vomiting. By multivariate logistic regression analysis, female sex (adjusted odds ratio [aOR], 2.69; 95% confidence interval [CI], 1.62-4.47), >= 10 days of LZD administration (aOR, 2.57; CI, 1.46-4.50), and hyponatraemia (aOR, 2.96; CI, 1.72-5.10) were identified as independent risk factors for vomiting; administration of serotonergic agents (aOR, 0.23; CI, 0.07-0.82) was negatively associated. Conclusions This study is the first to successfully identify risk factors for LZD-induced vomiting. Careful monitoring of patients with these risk factors may lead to safer and sustainable LZD administration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink